ICU, Myocardial Injury
Conditions
Brief summary
The study was a single-center, randomized controlled pilot study. To explore the cardioprotective effect of cardiopeptidin on non-heart disease patients with severe cardiac injury by comparing whether cardiopeptidin was used.
Interventions
DRUGCardiopeptidin
Cardiopeptidin was administered intravenously once a day with cardiopeptidin for 3 days.The dosing regimen follows the recommended dosage of 1 mg/kg/day as outlined in the product manual, with doses calculated based on the ideal body weight.
DRUG50 ml of normal saline intravenous infusion
50 ml of normal saline intravenous infusion
Sponsors
Nanfang Hospital, Southern Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years old 2. The high-sensitive troponin T index was higher than the normal value during ICU hospitalization 3. Obtain the informed consent of the subject or legal agent
Exclusion criteria
1. Patients who are expected to die within 48 hours of ICU admission 2. previous diagnosis of acute coronary syndrome, chronic cardiomyopathy, pulmonary heart disease, acute myocarditis, pericardial tamponade and other diseases that have been confirmed to cause myocardial injury 3. cardiopulmonary resuscitation and/or electrical defibrillation before admission 4. patients with acute ischemic stroke 5. patients with stage 5 chronic kidney disease 6. during pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| major adverse cardiac events | On the day of enrollment, until 28 days. | major adverse cardiac events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 28-day all-cause mortality | 28-day | 28-day all-cause mortality |
| 90-day all-cause mortality | 90-day | 90-day all-cause mortality |
| Cardiac adverse events | In hospital, until the patient is discharged. | Cardiac adverse events |
| LVEF | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | LVEF |
| APACHE II | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | APACHE II |
| Hypersensitive troponin T | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks |
| MB | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | MB |
| NT-Pro BNP | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | NT-Pro BNP |
| LDH | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | LDH |
| α-HBDH | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | α-HBDH |
| CK | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | CK |
| CKMB | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | CKMB |
| Lac | On the day of enrollment, 1/4/7/14 days after enrollment，up to two weeks | Lac |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORzhenhua zeng
Nanfang Hospital, Southern Medical University
Outcome results
None listed